skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure

Original Research

(3276) Views  (775) Full article downloads

Authors: Inder S Anand, Anita Deswal, Dean J Kereiakes, et al

Published Date June 2010 Volume 2010:6 Pages 449 - 455
DOI: http://dx.doi.org/10.2147/VHRM.S11090

Inder S Anand1, Anita Deswal2, Dean J Kereiakes3, Das Purkayastha4, Dion H Zappe4

1Veterans Administration Medical Center, Minneapolis, MN, USA; 2Michael E DeBakey VA Medical Center, Houston, TX, USA; 3The Christ Hospital Heart and Vascular Center, Cincinnati, OH, USA; 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Clinical trial registration information: www.clinicaltrials.gov/ct2/show/NC T00294086 Unique identification number: NC T00294086

Background: The safety of once-daily (qd) dosing of valsartan in heart failure (HF) patients is not known. Hypothesis: This 10-week, double-blind trial examined the relative safety and efficacy of valsartan administered qd versus twice-daily (bid).

Methods: HF patients (NYHA class II–III) receiving diuretics (87%), angiotensin-converting enzyme inhibitors (98%), beta-blockers (92%), aldosterone antagonists (25%), or digoxin (32%) were randomized to valsartan 40 mg bid (n = 60) or 80 mg qd (n = 55) and titrated to a maximum dose of 320 mg/day; doubling the dose every 2 weeks. Clinical and biochemical parameters were measured at Weeks 2, 4, 6, and 10.

Results: The average dose of valsartan at the end of study was 245 mg in the bid group vs 256 mg in the qd group (P = NS). Similar proportions of patients tolerated qd vs bid dosing (bid 67% vs qd 68%). Outcome measures including reduction in blood pressure, incidence of hypotension, renal impairment, orthostatic dizziness or fatigue, changes in serum K+, creatinine, cystatin-C, and estimated glomerular filtration rate were similar between the 2 groups at all time-points. Brain natriuretic peptide levels decreased and plasma renin activity increased from baseline by the same amount in both groups at all time-points.

Conclusion: Valsartan administered qd has a similar safety and tolerability profile with comparable 24-hour RAAS blockade, as assessed by increases in PRA, as bid dosing in patients with moderate to severe (NYHA class II–III) heart failure.

Keywords: heart failure, angiotensin receptor blocker, valsartan








Readers of this article also read:

Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update
Role of triple fixed combination valsartan, amlodipine and hydrochlorothiazide in controlling blood pressure
Optimal use of β-blockers in high-risk hypertension: A guide to dosing equivalence
Estimating glomerular filtration rate in a population-based study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University